Maison Solutions Inc. - Class A Common Stock (MSS)
1.0095
-0.0205 (-1.99%)
NASDAQ · Last Trade: Apr 5th, 11:25 AM EDT

Via Benzinga · December 17, 2024

Via Benzinga · October 22, 2024

Via Benzinga · October 4, 2024

Via Benzinga · October 3, 2024

Maison Solutions just reported results for the fourth quarter of 2024.
Via InvestorPlace · August 14, 2024

Maison Solutions just reported results for the third quarter of 2024.
Via InvestorPlace · March 18, 2024

Maison Solutions just reported results for the second quarter of 2024.
Via InvestorPlace · December 18, 2023

Via Benzinga · September 24, 2024

Maison Solutions shares are trading higher Tuesday after the company reported its first-quarter financial results after Monday's closing bell. Here's a look at the details from the report:
Via Benzinga · September 24, 2024

Via Benzinga · September 24, 2024

Via Benzinga · September 24, 2024

Via Benzinga · September 2, 2024

Shares of Sharps Technology, Inc. (NASDAQ:STSS) rose sharply in today's pre-market trading after the company announced it received two purchase orders for a total of approximately one million SecureGard syringes for 2024 delivery.
Via Benzinga · July 5, 2024

We're starting the trading week with a breakdown of the biggest pre-market stock movers worth reading about for Monday morning!
Via InvestorPlace · February 12, 2024

Via Benzinga · February 8, 2024

Via Benzinga · January 26, 2024

The most oversold stocks in the consumer staples presents an opportunity to buy into undervalued companies.
Via Benzinga · January 10, 2024

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
Via Benzinga · December 28, 2023

Via Benzinga · December 26, 2023

Via Benzinga · December 21, 2023

It's time to dive into the biggest pre-market stock movers as we check out all of the most recent news for Tuesday morning!
Via InvestorPlace · December 19, 2023

Via Benzinga · December 18, 2023

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) rose sharply in pre-market trading after the FDA approved company’s ZORYVE topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals aged 9 years and older.
Via Benzinga · December 18, 2023

Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic castration-resistant prostate cancer.
Via Benzinga · December 18, 2023